STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3174 by analyst upside · 2026-06-27
ELV
Elevance Health, Inc.
Healthcare · Market Cap $86B · P/E 16.8x
ANALYST PRICE TARGET
+5.9%
implied upside to consensus target
Current Price $395.18
Consensus Target $418.67
Bull Target $498.0
Bear Target $331.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
8
Sell
0
52-Week Low $273.71
52-Week High $426.98
YTD Return +12.7%
FUNDAMENTALS
Market Cap $86B
P/E Ratio (TTM) 16.8x
Forward P/E 13.5x
EPS (TTM) $23.59
PEG Ratio 1.41
Dividend Yield 1.78%
Revenue (TTM) $200.4B
Profit Margin 2.6%
52-WEEK RANGE
52-Week Low $273.71
52-Week High $426.98
Current Price $395.18
Bear Target $331.0
Bull Target $498.0
● Now $395.18 ● Target $418.67
TRADING DATA
Avg Volume 1.7M
YTD Return +12.7%
Analyst Count 21
Consensus Buy
Upside to Target +5.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Elevance Health, Inc. (ELV) is currently trading at $395.18 with a Wall Street consensus price target of $418.67, implying potential upside of 5.9% over the next 12 months. 21 analysts currently cover ELV, with a consensus rating of Buy - 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $498.0, while the most cautious has a target of $331.0.

ELV operates in the Healthcare sector with a market capitalisation of $86B. The stock is up 12.7% year-to-date and is currently trading near the upper end of its 52-week range of $273.71 – $426.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ELV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho — Reiterated
Outperform → Outperform 2026-06-08 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-06-08 43% win rate (7 calls)
B of A Securities — Reiterated
Buy → Buy 2026-06-04 Building track record
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-06-04 Building track record
Truist Securities — Reiterated
Buy → Buy 2026-06-01 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-05-26 Building track record
UBS — Reiterated
Buy → Buy 2026-05-22 33% win rate (6 calls)
Mizuho — Reiterated
Outperform → Outperform 2026-05-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
60
out of 100
Coverage depth
24/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →